Understanding Rpth Recap Thromboprophylaxis W Rivaroxaban In Patients W Malignancy Central Venous Lines
Exploring Rpth Recap Thromboprophylaxis W Rivaroxaban In Patients W Malignancy Central Venous Lines reveals several interesting facts. Watch Rick Ikesaka, M.D. and Mandy Lauw M.D., Ph.D. discuss the recent
Key Takeaways about Rpth Recap Thromboprophylaxis W Rivaroxaban In Patients W Malignancy Central Venous Lines
- Dr Soff talks to ecancertv at ASH 2015 about a quality assessment initiative that looked at the use of the oral anticoagulant ...
- Alok Khorana, MD, talks about results from the CALLISTO trial and the need for new treatments for
- Watch
- Alok Khorana, MD, of the Cleveland Clinic joins Blood &
- It's a well-known fact that
Detailed Analysis of Rpth Recap Thromboprophylaxis W Rivaroxaban In Patients W Malignancy Central Venous Lines
Watch as Victoria Speed and Geoff Barnes discuss this recent paper from Research and Practice in Thrombosis and Haemostasis ... The CASSINI trial investigated the use of Rivaroxaban for thromboprophylaxis in high risk ambulatory patients with cancer
Watch Anna Tran and Anna Falanga, M.D., discuss this recent article published in
Stay tuned for more updates related to Rpth Recap Thromboprophylaxis W Rivaroxaban In Patients W Malignancy Central Venous Lines.